Medifast Shifts to Metabolic Health: A Durable Growth Path?
MED is pivoting to metabolic health, using clinical data and new products to address root causes beyond GLP-1 weight loss.
Medifast New Product Line Planned: Can Innovation Reignite Demand?
MED plans a new product line rooted in metabolic synchronization science, upgrading its core offerings as it shifts beyond weight loss.
Medifast's Third-Quarter Revenue Fell 36%: Is Stabilization Near?
MED witnesses revenue plunge as its coach base shrank, but restructuring and productivity initiatives aim to stabilize results by late 2025.
Can Medifast Overcome GLP-1 Pressure With Its Growth Strategy?
MED targets long-term metabolic health with programs that preserve muscle and support lasting wellness amid GLP-1 adoption.
Medifast's Q3 Loss Wider Than Expected, Sales Decline 36% Y/Y
MED's third-quarter results reflect pressure from fewer active OPTAVIA Coaches, but it is steering toward metabolic health for growth.
Medifast, Inc. (MED) Q3 2025 Earnings Call Transcript
Medifast, Inc. ( MED ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Steven Zenker - Vice President of Investor Relations Daniel Chard - Executive Chairman & CEO James Maloney - Chief Financial Officer Nicholas Johnson - Chief Field Operations Officer Conference Call Participants James Salera - Stephens Inc., Research Division Presentation Operator Greetings, and welcome to the Medifast Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
Medifast (MED) Up 6.5% Since Last Earnings Report: Can It Continue?
Medifast (MED) reported earnings 30 days ago. What's next for the stock?
Medifast Bolsters Growth Through Health & Wellness Solutions
MED is expanding OPTAVIA, digital tools and wellness offerings to drive long-term growth and strengthen customer ties.
Medifast, Inc. (MED) Q2 2025 Earnings Call Transcript
Medifast, Inc. (NYSE:MED ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Daniel R. Chard - Executive Chairman & CEO James P.
Medifast: Coach Surge Fuels Growth
Initiate Medifast with Strong Buy and $56 PT, citing overlooked operational inflection and coach network momentum driving above-consensus FY26 revenue growth. ASCEND product line and digital engagement tools are key catalysts, improving client retention, coach productivity, and setting the stage for a top line comeback. Valuation is anchored on a conservative 1.3x forward P/S multiple, offering asymmetric risk/reward with tangible execution momentum and significant rerating potential.
Medifast (MED) Up 10.9% Since Last Earnings Report: Can It Continue?
Medifast (MED) reported earnings 30 days ago. What's next for the stock?
Medifast Q1 Loss Wider Than Expected, Sales Down 33.8% Y/Y
MED's first-quarter results show challenges from fewer active OPTAVIA Coaches. Nonetheless, the company is focusing on revitalizing its coach base for growth.
